Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance.

ABSTRACT:

Background

Prostate cancer is the most common cancer in men and second leading cause of cancer-related deaths. Changes in screening guidelines, adoption of active surveillance (AS), and implementation of high-cost technologies have changed treatment costs. Traditional cost-effectiveness studies rely on clinical trial protocols unlikely to capture actual practice behavior, and existing studies use data predating new technologies. Real-world evidence reflecting these changes is lacking.

Objective

To assess real-world costs of first-line prostate cancer management.

Design setting and participants

We used clinical electronic health records for 2008-2018 linked with the California Cancer Registry and the Medicare Fee Schedule to assess costs over 24 or 60 mo following diag

SUBMITTER: Magnani CJ 

PROVIDER: S-EPMC7751921 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature